A Study of Pertuzumab in Participants With Prostate Cancer
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in
participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
Participants will be enrolled in two stages, the first (Cohort A) at a lower 420-mg dose and
the second (Cohort B) at a higher 1050-mg dose based upon observations in Cohort A. Up to 50
participants may enter either cohort, for a total enrollment between 46 and 73 participants
across 9 study centers.